Condition
CNS Tumor, Adult
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07243470Phase 1Recruiting
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
NCT06104488Phase 1Recruiting
A Study of Avutometinib for People With Solid Tumor Cancers
NCT00313729Phase 2CompletedPrimary
Temozolomide in Treating Patients With Low-Grade Glioma
NCT01920191Phase 1CompletedPrimary
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
NCT00274833Phase 2CompletedPrimary
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Showing all 5 trials